However, a systematic review by McGeorge et al. revealed that incorporating 2-[18F]FDG PET after PSMA PET could enhance metastasis detection rates in high-risk, early-stage castration-resistant prostate cancer patients from 65 to 73%, even when conventional imaging fails to reveal abnormalities. Here, FOLH1 is linked to prostate cancer.